Vir Biotechnology, Inc. (VIR) Stock
Vir Biotechnology stock price chart
VIR stock quote & key statistics
Vir Biotechnology annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $68.6M | -$438.0M | -$3.16 |
| FY2024 | $74.2M | -$522.0M | -$3.82 |
| FY2023 | $86.2M | -$615.1M | -$4.59 |
| FY2022 | $1.62B | $515.8M | $3.81 |
| FY2021 | $1.10B | $528.6M | $3.88 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a leading immunology company operating in the commercial stage, dedicated to advancing therapeutic solutions for the treatment and prevention of serious infectious diseases. The company's robust pipeline includes innovative products targeting a spectrum of viral infections.
Among its key developments, Vir Biotechnology is advancing Sotrovimab (VIR-7832), a potent SARS-CoV-2-neutralizing monoclonal antibody marketed under the Xevudy brand. This treatment is designed to both treat and prevent COVID-19 infections, showcasing the company's commitment to combating global health challenges.
In addition to Sotrovimab, Vir Biotechnology is actively pursuing VIR-2218 and VIR-3434 for the treatment of hepatitis B virus, VIR-2482 for influenza A virus prevention, and VIR-1111 for human immunodeficiency virus prevention. These initiatives highlight the company's diverse portfolio aimed at addressing critical medical needs worldwide.
Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology has forged strategic partnerships and collaborations with prominent entities such as the Bill & Melinda Gates Foundation, National Institutes of Health, and several biopharmaceutical leaders. These alliances underscore Vir Biotechnology's commitment to leveraging cutting-edge science and collaborative innovation to accelerate the development and delivery of transformative therapies.
Vir Biotechnology stock FAQ
What is the Vir Biotechnology stock ticker symbol?
Vir Biotechnology, Inc. trades on the NASDAQ under the ticker symbol VIR.
What sector and industry is Vir Biotechnology in?
Vir Biotechnology, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does Vir Biotechnology have?
Vir Biotechnology, Inc. has about 367 full-time employees.
What were Vir Biotechnology's revenue and earnings last fiscal year?
Vir Biotechnology reported revenue of $68.6M and net income of -$438.0M in fiscal 2025, with earnings per share of -$3.16. Revenue declined 7.6% from the prior year.
Is Vir Biotechnology in the S&P SmallCap 600?
Yes. Vir Biotechnology, Inc. (VIR) is a component of the S&P SmallCap 600, the benchmark index of profitable U.S. small-cap stocks.
Is Vir Biotechnology in the Russell 2000?
Yes. Vir Biotechnology, Inc. (VIR) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.
When did Vir Biotechnology go public?
Vir Biotechnology stock began trading on October 11, 2019.
S&P SmallCap 600 Biotechnology stocks
All S&P SmallCap 600 →- ACADACADIA Pharmaceuticals
- ADMAADMA Biologics
- ALKSAlkermes
- ARQTArcutis Biotherapeutics
- CONConcentra Group Holdings Parent
- FTREFortrea
- GKOSGlaukos
- HRMYHarmony Biosciences
- ICUIICU Medical
- INDVIndivior
- INVAInnoviva
- ITGRInteger
- LGNDLigand Pharmaceuticals
- MMSIMerit Medical Systems
- OGNOrganon
- PTCTPTC Therapeutics
- PTGXProtagonist Therapeutics
- RCUSArcus Biosciences
- RDNTRadNet
- SRPTSarepta Therapeutics
- TFXTeleflex
- TGTXTG Therapeutics
- VCELVericel
- XNCRXencor